MMRF’s MyDRUG Platform Trial Aims For Efficiency In Testing Treatments For Myeloma Mutations
The adaptive trial design will help test smaller subpopulations and could lead to more effective and cost-efficient treatment strategies.
You may also be interested in...
As new drugs move into earlier lines of therapy for use in combination and for longer periods, payers are growing more sensitive to myeloma therapies' costs in the US and major ex-US markets.
CDER director renews US FDA's support for complex trials, but acknowledges that sponsors are still hesitant to adopt them.
Pioneering enrollment strategies are coupled with adaptive statistical designs in the next wave of basket trials from NCI, ASCO and Novartis.